GLPwatch
Papers (10401)
Page 19 of 174, ranked by citation count.
- Quality by design thinking in the development of long-acting injectable PLGA/PLA-based microspheres for peptide and protein drug delivery.
- Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study.
- Glucagon-like peptide 1, insulin, sensory neurons, and diabetic neuropathy.
- Efficacy and Safety of Semaglutide for Weight Loss in Obesity Without Diabetes: A Systematic Review and Meta-Analysis.
- Association of pancreatitis with glucagon-like peptide-1 agonist use.
- Liraglutide Protects Against Brain Amyloid-β<sub>1-42</sub> Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation.
- Tirzepatide for the treatment of obesity: Rationale and design of the SURMOUNT clinical development program.
- Brain region specific glucagon-like peptide-1 receptors regulate alcohol-induced behaviors in rodents.
- Exendin-4 protects against post-myocardial infarction remodelling via specific actions on inflammation and the extracellular matrix.
- Synaptotagmin-7 phosphorylation mediates GLP-1-dependent potentiation of insulin secretion from β-cells.
- Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes.
- Liraglutide attenuates type 2 diabetes mellitus-associated non-alcoholic fatty liver disease by activating AMPK/ACC signaling and inhibiting ferroptosis.
- Changes in Glucose Metabolism and Glycemic Status With Once-Weekly Subcutaneous Semaglutide 2.4 mg Among Participants With Prediabetes in the STEP Program.
- GLP-1 Receptor Agonists: A New Treatment in Parkinson's Disease.
- Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
- Effect of 12-week dulaglutide therapy in Japanese patients with biopsy-proven non-alcoholic fatty liver disease and type 2 diabetes mellitus.
- Liraglutide Compromises Pancreatic β Cell Function in a Humanized Mouse Model.
- Tirzepatide Once Weekly for the Treatment of Obesity. Reply.
- Liraglutide improves cognitive impairment via the AMPK and PI3K/Akt signaling pathways in type 2 diabetic rats.
- Neuroprotective effect of liraglutide in an experimental mouse model of multiple sclerosis: role of AMPK/SIRT1 signaling and NLRP3 inflammasome.
- Cardioprotective effects of exenatide against oxidative stress-induced injury.
- A Novel CCK-8/GLP-1 Hybrid Peptide Exhibiting Prominent Insulinotropic, Glucose-Lowering, and Satiety Actions With Significant Therapeutic Potential in High-Fat-Fed Mice.
- Lack of effect of the glucagon-like peptide-1 receptor agonist liraglutide on psoriasis in glucose-tolerant patients--a randomized placebo-controlled trial.
- Do GLP-1 Receptor Agonists Increase the Risk of Breast Cancer? A Systematic Review and Meta-analysis.
- Liraglutide prevents and reverses monocrotaline-induced pulmonary arterial hypertension by suppressing ET-1 and enhancing eNOS/sGC/PKG pathways.
- Sperm count is increased by diet-induced weight loss and maintained by exercise or GLP-1 analogue treatment: a randomized controlled trial.
- Dynamics of GLP-1R peptide agonist engagement are correlated with kinetics of G protein activation.
- The GLP-1 Receptor Agonist Liraglutide Increases Myocardial Glucose Oxidation Rates via Indirect Mechanisms and Mitigates Experimental Diabetic Cardiomyopathy.
- Lixisenatide for type 2 diabetes mellitus.
- Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial.
- In vitro protein binding of liraglutide in human plasma determined by reiterated stepwise equilibrium dialysis.
- Amylase, Lipase, and Acute Pancreatitis in People With Type 2 Diabetes Treated With Liraglutide: Results From the LEADER Randomized Trial.
- Psychiatric adverse events associated with semaglutide, liraglutide and tirzepatide: a pharmacovigilance analysis of individual case safety reports submitted to the EudraVigilance database.
- Safety and efficacy of a GLP-1 and glucagon receptor dual agonist mazdutide (IBI362) 9 mg and 10 mg in Chinese adults with overweight or obesity: A randomised, placebo-controlled, multiple-ascending-dose phase 1b trial.
- Cardiovascular effects of glucagonlike peptide-1 agonists.
- Glucagon-like peptide 1-related peptides increase nitric oxide effects to reduce platelet activation.
- Short-term intervention with liraglutide improved eating behavior in obese women with polycystic ovary syndrome.
- Semaglutide and diuretic use in obesity-related heart failure with preserved ejection fraction: a pooled analysis of the STEP-HFpEF and STEP-HFpEF-DM trials.
- Lack of Durable Improvements in β-Cell Function Following Withdrawal of Pharmacological Interventions in Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes.
- Novel Diabetes Drugs and the Cardiovascular Specialist.
- SIRT1/HSF1/HSP pathway is essential for exenatide-alleviated, lipid-induced hepatic endoplasmic reticulum stress.
- The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics.
- Largest single-centre experience of dulaglutide for management of diabetes mellitus in solid organ transplant recipients.
- A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.
- Activation of glucagon-like peptide-1 receptors in the nucleus accumbens attenuates cocaine seeking in rats.
- Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfaction.
- Inflammation in Obesity-Related HFpEF: The STEP-HFpEF Program.
- Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output.
- Association of semaglutide with reduced incidence and relapse of cannabis use disorder in real-world populations: a retrospective cohort study.
- What Effects Might Exenatide have on Non-Motor Symptoms in Parkinson's Disease: A Post Hoc Analysis.
- Effects of exenatide and open-label SGLT2 inhibitor treatment, given in parallel or sequentially, on mortality and cardiovascular and renal outcomes in type 2 diabetes: insights from the EXSCEL trial.
- Effects of glycaemic management on diabetic kidney disease.
- Effects of liraglutide on left ventricular function in patients with non-ST-segment elevation myocardial infarction.
- Glucagon-like peptide-1 analogue therapy for psoriasis patients with obesity and type 2 diabetes: a prospective cohort study.
- Effects of GLP-1 Receptor Agonists on Bone Mineral Density in Patients with Type 2 Diabetes Mellitus: A 52-Week Clinical Study.
- Design and Baseline Characteristics of STEP-HFpEF Program Evaluating Semaglutide in Patients With Obesity HFpEF Phenotype.
- Exenatide alleviates mitochondrial dysfunction and cognitive impairment in the 5×FAD mouse model of Alzheimer's disease.
- Once-Weekly Subcutaneous Semaglutide Improves Fatty Liver Disease in Patients with Type 2 Diabetes: A 52-Week Prospective Real-Life Study.
- Oral semaglutide improves postprandial glucose and lipid metabolism, and delays gastric emptying, in subjects with type 2 diabetes.
- Liraglutide dictates macrophage phenotype in apolipoprotein E null mice during early atherosclerosis.